Granger S E, Hollingsworth M, Weston A H
Br J Pharmacol. 1985 May;85(1):255-62. doi: 10.1111/j.1476-5381.1985.tb08854.x.
An assessment was made of the potencies of nifedipine, gallopamil, diltiazem, cinnarizine and salbutamol as inhibitors of tension development by the uterus and cardiovascular tissues from the term pregnant rat. The rank order of potency was nifedipine greater than gallopamil greater than diltiazem for those preparations on which these compounds were potent, viz. spontaneous and oxytocin-induced tension development of the uterus, spontaneous tension development of hepatic portal vein, potassium chloride (KCl)-induced pressure rises of perfused mesenteric bed and electrically-stimulated (0.5 Hz) ventricular muscle. The rank order of potency of nifedipine, gallopamil and diltiazem was different for those preparations on which they exhibited low potency, viz. noradrenaline-induced pressure rises of perfused mesenteric bed and tension development of aorta. Gallopamil and diltiazem, but not nifedipine, were more potent against tension development by ventricular muscle stimulated at 2.5 Hz than at 0.5 Hz, suggesting that nifedipine interacts at a different site from the other compounds. Cinnarizine was less potent than the other calcium antagonists on the uterus and portal vein, was the second most potent compound against KCl-induced pressure rises of the mesenteric bed and was equipotent against responses to noradrenaline and KCl of the mesenteric bed (unlike the other compounds). This suggests that the site of action of cinnarizine differs from that of the other calcium antagonists. Nifedipine, gallopamil and diltiazem, like salbutamol, exhibited selectivity for inhibition of tension development by the uterus relative to the cardiovascular tissues.
对硝苯地平、加洛帕米、地尔硫䓬、桂利嗪和沙丁胺醇作为足月妊娠大鼠子宫和心血管组织张力发展抑制剂的效力进行了评估。对于这些化合物有效的制剂,效力的排序为硝苯地平>加洛帕米>地尔硫䓬,即子宫的自发和催产素诱导的张力发展、肝门静脉的自发张力发展、氯化钾(KCl)诱导的灌注肠系膜床压力升高以及电刺激(0.5Hz)心室肌。对于硝苯地平、加洛帕米和地尔硫䓬效力较低的制剂,其效力排序不同,即去甲肾上腺素诱导的灌注肠系膜床压力升高和主动脉的张力发展。加洛帕米和地尔硫䓬,但不是硝苯地平,对2.5Hz刺激的心室肌张力发展的抑制作用比对0.5Hz刺激的更强,这表明硝苯地平与其他化合物的作用位点不同。桂利嗪在子宫和门静脉上的效力低于其他钙拮抗剂,是对抗KCl诱导的肠系膜床压力升高的第二有效化合物,并且对肠系膜床对去甲肾上腺素和KCl的反应效力相同(与其他化合物不同)。这表明桂利嗪的作用位点与其他钙拮抗剂不同。硝苯地平、加洛帕米和地尔硫䓬与沙丁胺醇一样,相对于心血管组织,对子宫张力发展的抑制具有选择性。